PNC Financial Services Group
TRAX

PNC Financial Services Group’s First Tracks Biotherapeutics TRAX Stock Holding History

PNC Financial Services Group’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.65K Buy
+231
New +$4.32K ﹤0.01% 4417

Other funds holding TRAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
FEG
Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PNC Financial Services Group's TRAX Position: Q2 2026 in Review

PNC Financial Services Group opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 231 shares worth $4.65K. The stake represents ﹤0.01% of the portfolio and ranks #4417 among its holdings.

38 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • PNC Financial Services Group held 231 shares of First Tracks Biotherapeutics worth $4.65K as of Q2 2026.
  • First Tracks Biotherapeutics was a new PNC Financial Services Group position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4417 holding.
  • 38 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.